

January 27, 2017

### **Carna Biosciences Announces Research Collaboration with EpiBiome**

Carna Biosciences announced today that it has entered into a research collaboration with EpiBiome, South San Francisco, CA, that will seek to develop potential new treatments in the area of microbiome. Under the agreement, Carna and EpiBiome will jointly develop a new therapeutic concept to discover innovative therapy for the treatment of various diseases associated with the microbiome. The collaboration will leverage both companies' strengths, Carna's capabilities in small molecule drug discovery and EpiBiome's deep knowledge and proprietary technologies in the microbiome field.

"We are very pleased to enter into this collaboration with EpiBiome, on microbiome platform which offers a new way to develop innovative therapy," said Kohichiro Yoshino, PhD, Founder, President and CEO of Carna Biosciences. "We opened C-Lab in the US last year, and this collaboration is the results of networking at JLABS."

"We are very excited to work with EpiBiome team to step in microbiome research, a newly discovered and largely unexplored field," added Dr. Masaaki Sawa, Chief Scientific Officer of Carna. "By combining EpiBiome's proprietary microbiome platform with Carna's expertise in the field of small molecule drug discovery, we can invent novel methodology for treating challenging diseases."

"EpiBiome is very impressed by Carna's drug discovery expertise in the area of kinase inhibitors. We look forward to a successful collaboration with Carna to harness microbiome functions," said Nick Conley, PhD, CEO and Co-founder of EpiBiome. "We are very excited to establish this partnership with Carna to engage in microbiome profiling and to identify drug candidates for treatment of microbiome-associated diseases," added Christina Tsai, PhD, Chief Science Officer and Co-founder of EpiBiome.

#### **About EpiBiome, Inc.**

EpiBiome is a precision microbiome engineering company with the mission of developing effective and sustainable FDA-approved therapies to combat infectious disease in humans and in agriculture without the use of small-molecule antibiotics.

The company's management team consists of Nick Conley, PhD (Chief Executive Officer & Co-founder), Aeron Tynes Hammack, PhD (Chief Operating Officer & Co-founder), Christina Tsai, PhD (Chief Science Officer & Co-founder), Lucia Mokres, DVM (Chief Medical Officer), and Bruno Marchon, PhD (Chief Technical Officer). EpiBiome is located at 201 Gateway Blvd., South San Francisco.

For more information, visit <http://www.epibiome.com>.